Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level

European Journal of Cancer

Volumn 49, Issue 4, 2013, Pages 938-945

  Veitonmäki, Thea ^a,b   Tammela, Teuvo L J ^a,b   Auvinen, Anssi ^a   Murtola, Teemu J ^c,d  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Central Finland Central Hospital   (Finland)

Author keywords

Aspirin; Case control study; COX2; NSAIDs; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; KETOPROFEN; PARACETAMOL; ROFECOXIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; HUMAN; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FINLAND; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; YOUNG ADULT;

EID: 84873719461     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.09.030     Document Type: Article

References (40)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 4 2010 765 781
2. F. Bray, J. Lortet-Tieulent, J. Ferlay, D. Forman, and A. Auvinen Prostate cancer incidence and mortality trends in 37 European countries: an overview Eur J Cancer 46 17 2010 3040 3052
3. E.D. Crawford Understanding the epidemiology, natural history, and key pathways involved in prostate cancer Urology 73 5 Suppl. 2009 S4 S10
4. G.D. Steinberg, B.S. Carter, T.H. Beaty, B. Childs, and P.C. Walsh Family history and the risk of prostate cancer Prostate 17 4 1990 337 347
5. A.M. De Marzo, E.A. Platz, and S. Sutcliffe Inflammation in prostate carcinogenesis Nat Rev Cancer 7 2007 256 269
6. T. Hussain, S. Gupta, and H. Mukhtar Cyclooxygenase-2 and prostate carcinogenesis Cancer Lett 191 2003 125 135
7. S. Gupta, M. Srivastava, N. Ahmad, D.G. Bostwick, and H. Mukhtar Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma Prostate 42 1 2000 73 78
8. R. Yoshimura, H. Sano, and C. Masuda Expression of cyclooxygenase-2 in prostate carcinoma Cancer 89 3 2000 589 596
9. L. Khor, K. Bae, and A. Pollack T COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial Lancet Oncol 8 10 2007 912 920
10. A. Rostom, C. Dubé, and G. Lewin US Preventive Services Task Force. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force Ann Intern Med 146 5 2007 376 389
11. D.A. Corley, K. Kerlikowske, R. Verma, and P. Buffler Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis Gastroenterology 124 1 2003 47 56
12. W. Tian, Y. Zhao, S. Liu, and X. Li Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer Eur J Cancer Prev 19 4 2010 288 298
13. S.E. Daugherty, R.M. Pfeiffer, and A.J. Sigurdson Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis Am J Epidemiol 173 7 2011 721 730
14. P. Abedinpour, V.T. Baron, J. Welsh, and P. Borgström Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo Prostate 71 8 2011 813 823
15. S.M. Mahmud, E.L. Franco, and A.G. Aprikian Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis Int J Cancer 127 7 2010 1680 1691
16. L. Teppo, E. Pukkala, and M. Lehtonen Data quality and quality control of a population-based cancer registry Acta Oncol 33 4 1994 365 369
17. Martikainen J, Rajaniemi S. Drug reimbursement systems in EU member states, Iceland and Norway. Helsinki, Finland: The Social Insurance Institution, Finland, Social security and health reports 54; 2002. Available from: < http://www.kela.fi/in/internet/english.nsf/NET/100203115310PN >.
18. P.C. Austin, P. Grootendorst, and G.M. Anderson A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study Stat Med 26 4 2007 734 753
19. World Health Organization. ATC/DDD index database. < http://www.whocc.no/atcddd/indexdatabase/index.php?query=A10 >.
20. B. Cryer, and M. Feldman Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs Am J Med 104 1998 413 421
21. S.K. Kulkarni, N.K. Jain, and A. Singh Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors Methods Find Exp Clin Pharmacol 22 5 2000 291 298 [review]
22. C.A. Salinas, E.M. Kwon, and L.M. FitzGerald Use of aspirin and other nonsteroidal anti-inflammatory medications in relation to prostate cancer risk Am J Epidemiol 172 5 2010 578 590
23. E.J. Jacobs, C.C. Newton, V.L. Stevens, and S.M. Gapstur A large cohort study of long-term acetaminophen use and prostate cancer incidence Cancer Epidemiol Biomarkers Prev 20 7 2011 1322 1328
24. A.S. Murad, L. Down, and G. Davey Smith Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study) Int J Cancer 128 6 2011 1442 1448
25. H.T. Sørensen, S. Friis, and B. Nørgård Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study Br J Cancer 88 2003 1687 1692
26. T.M. Brasky, C.M. Velicer, and A.R. Kristal Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort Cancer Epidemiol Biomarkers Prev 19 12 2010 3185 3188
27. M.F. Leitzmann, M.J. Stampfer, and J. Ma Aspirin use in relation to risk of prostate cancer Cancer Epidemiol Biomarkers Prev 11 10 Pt. 1 2002 1108 1111
28. M.J. Langman, K.K. Cheng, E.A. Gilman, and R.J. Lancashire Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database BMJ 320 7250 2000 1642 1646
29. Y. Vinogradova, C. Coupland, and J. Hippisley-Cox Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies Br J Cancer 105 3 2011 452 459
30. S. Ciatto, M. Zappa, and A. Villers Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening BJU Int 92 Suppl. 2 2003 97 100
31. T.J. Murtola, P. Pennanen, and H. Syvälä Effects of simvastatin, acetylsalicylic acid and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations Prostate 69 9 2009 1017 1023
32. C. Bosetti, V. Rosato, S. Gallus, and C. La Vecchi Aspirin and urologic cancer risk: an update Nat Rev Urol 9 2 2012 102 110
33. T.M. Brasky, M.R. Bonner, and K.B. Moysich Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype Cancer Causes Control 22 7 2011 965 975
34. J.C. Frölich A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes Review Trends Pharmacol Sci 18 1 1997 30 34
35. H. Fujita, K. Koshida, and E.T. Keller Cyclooxygenase-2 promotes prostate cancer progression Prostate 53 3 2002 232 240
36. S.L. Chang, L.C. Harshman, and J.C. Presti Jr. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey J Clin Oncol 28 25 2010 3951 3957
37. M.U. Yood, U.B. Campbell, and K.J. Rothman Using prescription claims data for drugs available over-the-counter (OTC) Pharmacoepidemiol Drug Saf 16 9 2007 961 968
38. C. Nunzio, G. Kramer, and M. Marberger The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation Eur Urol 60 1 2011 106 117
39. Statistics Finland. Finland in figures: population structure. < http://www.stat.fi/til/vaerak/index.html >.
40. P. Lichtenstein, N.V. Holm, and P.K. Verkasalo Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland N Engl J Med 343 2 2000 78 85